Gene therapy for thyroid cancer

Expert Opinion on Biological Therapy

Volumn 4, Issue 8, 2004, Pages 1225-1239

  Barzon, Luisa ^a   Pacenti, Monia ^a   Boscaro, Marco ^b   Palù, Giorgio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Cancer treatment; Gene therapy; Immunotherapy; Thyroid cancer; Tumour targeting

Indexed keywords

AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; DNA VACCINE; ENDOSTATIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HIGH MOBILITY GROUP A1B PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; MYC PROTEIN; NITRIC OXIDE SYNTHASE; NORADRENALIN TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCALCITONIN; PROTEIN P53; PROTEIN P73; PROTEIN RET; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SODIUM IODIDE SYMPORTER; THYMIDINE KINASE; TRANSCRIPTION FACTOR E2F1; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VIRUS ONCOLYSATE;

ANEMIA; CANCER IMMUNOTHERAPY; CARCINOGENESIS; FATIGUE; FEVER; GENE REPLACEMENT THERAPY; GENE THERAPY; HUMAN; LIVER DYSFUNCTION; NAUSEA; ONCOGENE; REVIEW; SUICIDE GENE THERAPY; THYROID CANCER; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOLOGICAL THERAPY; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PROTO-ONCOGENES; RATS; THYROID NEOPLASMS; VIRUSES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3442899727     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.8.1225     Document Type: Review

References (146)

1. FRANCESCHI S, BOYLE P, MAISONNEUVE P et al.: The epidemiology of thyroid carcinoma. Crit. Rev. Oncog. (1993) 4:25-52.
2. GIMM O: Thyroid cancer. Cancer Lett. (2001) 163:143-156.
3. BAVERSTOCK K, EGLOFF B, PINCHERA A, RUCHTI C, WILLIAMS D: Thyroid cancer after Chernobyl. Nature (1992) 359:21-22.
4. rd, DRISCOLL D, BAKAMJIAN V, HICKS WL JR, SHEDD DP: Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck (1995) 17:41-47.
5. ENG C, MULLIGAN LM: Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumors, and hirschprung disease. Hum. Mutat. (1997) 9:97-109.
6. BARZON L, BONAGURO R, PALU G, BOSCARO M: New perspectives for gene therapy in endocrinology. Eur. J. Endocrinol. (2000) 143:447-466.
7. DEGROOT LJ, ZHANG R: Gene therapy for thyroid cancer: where do we stand? J. Clin. Endocrinol. Metab. (2001) 86:2923-2928.
8. GALANIS E, VILE R, RUSSELL S: Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit. Rev. Oncol. Hematol. (2001) 38:177-192.
9. BRAIDEN V, NAGAYAMA Y, IITAKA M, NAMBA H, NIWA M, YAMASHITA S: Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology (1998) 139:3996-3999. First demonstration of the feasibility of transcriptionally targeted gene therapy for DTCs.
10. ZHANG R, STRAUS FH, DEGROOT LJ: Cell-specific viral gene therapy of a Hurthle cell tumor. J. Clin. Endocrinol. Metab. (2002) 87:1407-1414.
11. ZHANG R, STRAUS FH, DEGROOT LJ: Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid (2001) 11:115-123.
12. KITAZONO M, CHUMAN Y, AIKOU T, FOJO T: Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3′,5′-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab. (2001) 86:834-840.
13. TAKEDA T, YAMAZAKI M, MINEMURA K et al.: A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas. Cancer Gene Ther. (2002) 9:864-874.
14. BARZON L, BONAGURO R, CASTAGLIUOLO I et al.: Transcriptionally-targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer. J. Clin. Endocrinol. Metab. (2002) 87:5304-5311. In vitro and animal experiments demonstrate the therapeutic efficacy of targeted HSV-TK/IL-2 gene therapy in DTC.
15. KITAZONO M, CHUMAN Y, AIKOU T, FOJO T: Adenovirus HSV-TK construct with thyroid-specific promoter: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cAMP pathway. Int. J. Cancer (2002) 99:453-459.
16. NAGAYAMA Y, NISHIHARA E, IITAKA M, NAMBA H, YAMASHITA S, NIWA M: Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res. (1999) 59:3049-3052. The Cre-loxP system, under the control of the thyroglobulin promoter, is used to enhance expression of therapeutic genes in thyroid cancer cells.
17. SHIMURA H, SUZUKI H, MIYAZAKI A et al.: Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells. Cancer Res. (2001) 61:3640-3646. Transcriptional targeting of ATC is achieved by co-expression of thyroid transcription factor-1 with TG promoter-driven therapeutic genes.
18. MINEMURA K, TAKEDA T, MINEMURA K et al.: Cell-specific induction of sensitivity to ganciclovir in medullary thyroid carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Endocrinology (2000) 141:1814-1822.
19. MESSINA M, YU DM, LEAROYD DL, BOTH GW, MOLLOY PL, ROBINSON BG: High level, tissue-specific expression of a modified calcitonin/calcitonin gene-related peptide promoter in a human medullary thyroid carcinoma cell line. Mol. Cell. Endocrinol. (2000) 164:219-224. Construction and characterisation of a chimeric enhancer/promoter sequence of the calcitonin/calcitonin gene-related peptide, showing high efficacy and tissue-specificity in MTC cells.
20. YAMAZAKI M, ZHANG R, STRAUS FH et al.: Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther. (2002) 9:64-74. Animal experiment to demonstrate the therapeutic efficacy of transcriptionally targeted IL-12 gene therapy for MTC.
21. YAMAZAKI M, STRAUS FH, MESSINA M et al.: Adenovirus-mediated tumor-specific combined gene therapy using herpes simplex virus thymidine/ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma. Cancer Gene Ther. (2004) 11:8-15.
22. FAGIN JA, MATSUO K, KARMAKAR A, CHEN DL, TANG SH, KOEFFLER HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. (1993) 91:179-184.
23. DONGHI R, LONGONI A, PILOTTI S, MICHIELI F, DELLA PORTA G, PIEROTTI MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. (1993) 91:1753-1760.
24. MORETTI F, FARSETTI A, SODDU S et al.: p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene (1997) 14:729-740. Demonstration that restoration of p53 activity in p53-null ATC cells leads to expression of thyroid differentiation genes, cell response to TSH and inhibition of cell proliferation.
25. FAGIN JA, TANG SH, ZEKI K, DI LAURO R, FUSCO A, GONSKY R: Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res. (1996) 56:765-771.
26. ZEKI K, TANAKA Y, MORIMOTO I et al.: Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53. Int. J. Cancer (1998) 75:391-395.
27. MORETTI F, NANNI S, FARSETTI A et al.: Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J. Clin. Endocrinol. Metab. (2000) 85:302-308.
28. NAGAYAMA Y, SHIGEMATSU K, NAMBA H, ZEKI K, YAMASHITA S, NIWA M: Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Res. (2000) 20:2723-2728.
29. NARIMATSU M, NAGAYAMA Y, AKINO K et al.: Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J. Clin. Endocrinol. Metab. (1998) 83:3668-3672.
30. BLAGOSKLONNY MV, GIANNAKAKOU P, WOJTOWICZ M et al.: Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J. Clin. Enaocrinol. Metab. (1998) 83:2516-2522.
31. KIM SB, AHN IM, PARK HJ et al.: Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. Head Neck (2001) 23:223-229.
32. IMANISHI R, OHTSURU A, IWAMATSU M et al.: A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J. Clin. Endocrinol. Metab. (2002) 87:4821-4824.
33. KITAZONO M, ROBEY R, ZHAN Z et al.: Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J. Clin. Endocrinol. Metab. (2001) 86:3430-3435.
34. KASTAN MB, ZHAN Q, EL-DEIRY WS et al.: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell(1992) 71:587-597.
35. DE SMAELE E, ZAZZERONI F, PAPA S et al.: Induction of Gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature (2001) 414:308-313.
36. CHUNG HK, YI YW, JUNG NC et al.: Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis. J. Clin. Endocrinol. Metab. (2003) 88:3913-3920. Demonstration that the Gadd45γ tumour suppressor gene has potential use for gene therapy in ATC.
37. ZHANG W, HUFFMAN B, LIEBERMANN DA: Ectopic expression of MyD118/Gadd45/CR6 (Gadd45β/α/γ) sensitizes neoplastic cells to genotoxic stress induced apoptosis. Int. J. Oncol. (2001) 18:749-757.
38. ZHANG L, MARTELLI ML, BATTAGLIA C et al.: Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. Exp. Cell Res. (1997) 235:62-70.
39. TRAPASSO F, IULIANO R, BOCCIA A et al.: Rat protein tyrosine phosphatase η suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol. Cell. Biol. (2000) 20:9236-9246.
40. IULIANO R, TRAPASSO F, LE PERA I et al.: An adenovirus carrying the rat protein tyrosine phosphatase η suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res. (2003) 63:882-886. Demonstration that transduction of the PTPη gene in ATC cells inhibits cell proliferation.
41. KROLL TG, SARRAF P, PECCIARlNI L et al.: PAX-8-PPAR1 fusion oncogene in human thyroid carcinoma. Science (2000) 289:1357. Identification of the PAX8-PPAR-1 fusion oncogene as a tumour-specific molecular event in thyroid tumourigenesis.
42. OHTA K, ENDO T, HARAGUCHI K, HERSHMAN JM, ONAYA T: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab. (2001) 86:2170-2177.
43. MARTELLI ML, IULIANO R, LE PERA I et al.: Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab. (2002) 87:4728-4735.
44. HALACHMI N, HALACHMI S, EVRON E et al.: Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer (1998) 23:239-243.
45. DAHIA PL, MARSH DJ, ZHENG Z et al.: Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. (1997) 57:4710-4713.
46. WENG LP, GIMM O, KUM JB et al.: Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum. Mol. Genet. (2001) 10:251-258.
47. JOST CA, MARIN MC, KAELIN WG JR: p73 is a human p53-related protein that can induce apoptosis. Nature (1997) 389:191-194.
48. FRASCA F, VELLA V, ALOISI A et al.: p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res. (2003) 63:5829-5837.
49. RODICKER F, STIEWE T, ZIMMERMANN S, PUTZER BM: Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res. (2001) 61:7052-7055.
50. ONDA M, NAGAI H, YOSHIDA A et al.: Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers. J. Hum. Genet. (2004) 49(6):312-318.
51. YAMASAKI L, BRONSON R, WILLIAMS BO, DYSON NJ, HARLOW E, JACKS T: Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-)mice. Nat. Genet. (1998) 18:360-364.
52. STIEWE T, PUTZER BM: Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat. Genet. (2001) 26:464-469.
53. BOSSI G, MAZZARO G, PORRELLO A, CRESCENZI M, SODDU S, SACCHI A: Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene (2004) 23:418-425.
54. MCNEISH IA, BELL SJ, LEMOINE NR: Gene therapy progress and prospects: cancer gene therapy using rumor suppressor genes. Gene Ther. (2004) 11:497-503.
55. BARZON L, BOSCARO M, PALU G: Endocrine aspects of cancer gene therapy. Endocr. Rev. (2004) 25:1-44. Updated review on clinical trials of cancer gene therapy and the potential endocrine side-effects of gene therapy.
56. SCHULER M, HERRMANN R, DE GREVE JL et al.: Adenovirus-mediated wild-type p 53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter Phase II study. J. Clin. Oncol. (2001) 19:1750-1758.
57. SWISHER SG, ROTH JA, NEMUNAITIS J et al.: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (1999) 91:763-771.
58. NEMUNAITIS J, SWISHER SG, TIMMONS T et al.: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. (2000) 18:609-622.
59. SWISHER SG, ROTH JA, KOMAKI R et al.: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. (2003) 9:93-101.
60. KIM DS, MCCABE CJ, BUCHANAN MA, WATKINSON JC: Oncogenes in thyroid cancer. Clin. Otolaryngol. (2003) 28:386-395.
61. LEMOINE NR, MAYALL ES, WILLIAMS ED, THURSTON V, WYNFORD-THOMAS D: Agent-specific ras oncogene activation in rat thyroid tumours. Oncogene (1988) 3:541-544.
62. DEL SENNO L, GAMBARI R, DEGLI UBERTI E et al.: c-myc oncogene alterations in human thyroid carcinomas. Cancer Detect. Prev. (1987) 10:159-166.
63. TERRIER P, SHENG ZM, SCHLUMBERG ER M et al.: Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas. Br. J. Cancer (1988) 57:43-47.
64. CHALLETON C, BOUNACER A, DU VILLARD JA et al.: Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Oncogene (1995) 11:601-603.
65. RUSSO D, ARTURI F, SCHLUMBERGER M et al.: Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene (1995) 11:1907-1911.
66. GIANCOTTI V, BERLINGIERI MT, DIFIORE PP, FUSCO A, VECCHIO G, CRANE-ROBINSON C: Changes in nuclear proteins on transformation of rat epithelial thyroid cells by a murine sarcoma retrovirus. Cancer Res. (1985) 45:6051-6057.
67. GIANCOTTI V, PANI B, D'ANDREA P et al.: Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by cotransfection with c-myc and polyoma middle T genes. EMBO J. (1987) 6:1981-1987.
68. CHIAPPETTA G, BANDIERA A, BERLINGIERI MT et al.: The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene (1995) 10:1307-1314.
69. CHIAPPETTA G, TALLINI G, DE BIASIO MC et al.: Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res. (1998) 58:4193-4198.
70. MULLIGAN LM, KWOK JB, HEALEY CS et al.: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 363:458-460.
71. DROSTEN M, PUTZER BM: Gene therapeutic approaches for medullary thyroid carcinoma treatment. J. Mol. Med. (2003) 81:411-419.
72. DROSTEN M, FRILLING A, STIEWE T, PUTZER BM: A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery (2002) 132:991-997.
73. DROSTEN M, STIEWE T, PUTZER BM: Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum. Gene Ther. (2003) 14:971-982. Demonstration that adenoviral delivery of a dominant-negative RET mutant gene, under the control of a synthetic C cell-selective calcitonin promoter, is effective against RET-oncogene-related MTC.
74. COSMA MP, CARDONE M, CARLOMAGNO F, COLANTUONI V: Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism. Mol. Cell. Biol. (1998) 18:3321-3329.
75. PARTHASARATHY R, COTE GJ, GAGEL RF: Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res. (1999) 59:3911-3914.
76. HENNIGE AM, LAMMERS R, HOPPNER W et al.: Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology (2001) 142:4441-4447.
77. QIAO S, IWASHITA T, FURUKAWA T, YAMAMOTO M, SOBUE G, TAKAHASHI M: Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins. J. Biol. Chem. (2001) 276:9460-9467.
78. CERUTTI J, TRAPASSO F, BATTAGLIA C et al.: Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. Clin. Cancer Res. (1996) 2:119-126.
79. BERLINGIERI MT, MANFIOLETTI G, SANTORO M et al.: Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol. Cell. Biol. (1995) 15:1545-1553.
80. SCALA S, PORTELLA G, FEDELE M, CHIAPPETTA G, FUSCO A: Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl. Acad. Sci. USA (2000) 97:4256-4261. Selective killing of ATC cells by delivery of the HMGI(Y) antisense sequence.
81. SEBOLT-LEOPOLD JS, DUDLEY DT, HERRERA R et al.: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. (1999) 5:810-816.
82. FREEMAN SM et al.: In vivo studies on the mechanism of the bystander effect. Cancer Gene Ther. (1994) 1:326-332.
83. BARBA D, HARDIN J, SADELAIN M, GAGE FH: Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA (1994) 91:4348-4352.
84. MULLEN CA et al.: Ganciclovir chemoablation of herpes rhymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses. Hum. Gene Ther. (1998) 9:2019-2030.
85. NISHIHARA E, NAGAYAMA Y, MAWATARI F et al.: Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology (1997) 138:4577-4583. First animal study reporting the efficacy of suicide gene therapy for thyroid cancer.
86. TAKEDA T, INABA H, YAMAZAKI M et al.: Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J. Clin. Endocrinol. Metab. (2003) 88:3531-3538.
87. ZHANG R, DEGROOT LJ: Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: relationship of bystander effect and antitumor efficacy. Thyroid (2000) 10:313-319.
88. JIANG S, ALTMANN A, GRIMM D et al.: Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther. (2001) 8:469-472.
89. SPITZWEG C, HARRINGTON KJ, PINKE LA, VILE RG, MORRIS JC: The sodium iodide symporter and its potential role in cancer therapy. J. Clin. Endocrinol. Metab. (2001) 86:3327-3335.
90. MANDELL RB, MANDELL LZ, LINK CJ JR: Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. (1999) 59:661-668. Demonstration that NIS-based gene therapy may have both diagnostic and therapeutic applications for cancer.
91. GROOT-WASSINK T, ABOAGYE EO, GLASER M, LEMOINE NR, VASSAUX G: Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum. Gene Ther. (2002) 13:1723-1735. In vivo imaging of ectopic NIS expression in xenograft rumour models by positron emission tomography.
92. MARSEE DK, SHEN DH, MACDONALD LR et al.: Imaging of metastatic pulmonary tumors following NIS gene transfer using single photon emission computed romography. Cancer Gene Ther. (2004) 11:121-127.
93. SMIT JW, SCHRODER-VAN DER ELST JP, KARPERIEN M, QUE I, ROMIJN JA, VAN DER HEIDE D: Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma. Exp. Clin. Endocrinol. Diabetes (2001) 109:52-55.
94. SMIT JW, SCHRODER-VAN DER ELST JP, KARPERIEN M et al.: Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a NIS defective human thyroid carcinoma cell line. Thyroid (2000) 10:939-943.
95. 131I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J. Clin. Endocrinol. Metab. (2002) 87:1247-1253.
96. HUANG M, BATRA RK, KOGAI T et al.: Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther. (2001) 8:612-618.
97. HABERKORN U: Gene therapy with sodium/iodide symporter in hepatocarcinoma. Exp. Clin. Endocrinol. Diabetes (2001) 109:60-62.
98. BOLAND A, MAGNON C, FILETTI S et al.: Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid (2002) 12:19-26.
99. 131I meta-iodobenzylguanidine. Gene Ther. (1999) 6:1147-1152.
100. BOYD M, MAIRS SC, STEVENSON K et al.: Transfected mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy. J. Gene Med. (2002) 4:567-576.
101. SOLER MN, BOBE P, BENIHOUD K, LEMAIRE G, ROOS BA, LAUSSON S: Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J. Gene Med. (2000) 2:344-352.
102. RAINOV NG: A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. (2000) 11:2389-2401.
103. LAUSSON S, FOURNES B, BORREL C, MILHAUD G, TREILHOU-LAHILLE F: Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma. Cancer Immunol. Immunother. (1996) 43:116-123.
104. ZHANG R, BAUNOCH D, DEGROOT LJ: Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene. Thyroid (1998) 8:1137-1146.
105. ZHANG R, STRAUS FH, DEGROOT LJ: Effective genetic therapy of established medullary thyroid carcinoma with murine interleukin-2: dissemination and cytotoxicity studies in a rat tumor model. Endocrinology (1999) 140:2152-2158. Animal study demonstrating that adenoviral vector-mediated delivery of IL-2 can efficiently eradicate xenograft MTC and confer immunity against rechallenge with wild-type tumor cells. No significant toxicity of IL-2 gene therapy to other organs.
106. ZHANG R, DEGROOT LJ: Genetic immunotherapy of established tumors with adenoviral vectors transducing murine interleukin-12 subunits in a rat medullary thyroid carcinoma model. Clin. Endocrinol. (Oxf.) (2000) 52:687-694.
107. SHI Y, PARHAR RS, ZOU M et al.: Gene therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein. Hum. Gene Ther. (2003) 14:1741-1751. Demonstration of efficacy of IL-12 gene therapy for ATC in a tumor xenograft model in nude mice. The antitumour activity was mainly mediated by natural killer cells.
108. SOLER MN, MILHAUD G, LEKMINE F, TREILHOU-LAHILLE F, KLATZMANN D, LAUSSON S: Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes. Cancer Immunol. Immunother. (1999) 48:91-99.
109. ZHANG R, DEGROOT LJ: An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma. Endocr. Relat. Cancer (2001) 8:315-325. Development of an adenoviral vector expressing both HSV-TKand hIL-2 for gene therapy of MTC and demonstration of an antitumour effect superior to that of each single therapeutic gene given alone.
110. BARZON L, BONAGURO R, CASTAGLIUOLO I et al.: Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Eur. J. Endocrinol. (2003) 148:73-80. Development of a retroviral vector co-expressing HSV- TKand hIL-2 and demonstration of its enhanced efficacy and in vivo bystander effect in DTC and ATC animal models.
111. PALU G, CAVAGGIONI A, CALVI P et al.: Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther. (1999) 6:330-337. First clinical trial of cancer gene therapy based on combined delivery of a suicide and a cytokine gene. Demonstration of safety and efficacy in patients with recurrent glioblastoma multiforme.
112. BARZON L, TACCALITI A, FRANCHIN E, PACENTI M, BOSCARO M, PALU G: Suicide/cytokine gene therapy in end-stage anaplastic thyroid carcinoma. Mol. Ther. (2002) 5:S386. First clinical study of gene therapy in patients with thyroid cancer based on combined delivery of a suicide and a cytokine gene. Treatment was safe.
113. BACHLEITNER-HOFMANN T, STIFT A, FRIEDL J et al.: Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. J. Clin. Endocrinol. Metab. (2002) 87:1098-1104.
114. SCHOTT M, SEISSLER J: Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies. Trends Endocnnol. Metab. (2003) 14:156-162.
115. SCHOTT M, SEISSLER J, LETTMANN M, FOUXON V, SCHERBAUM WA, FELDKAMP J: Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J. Clin. Endocrinol. Metab. (2001) 86:4965-4969. Clinical trial of DC vaccination therapy in patients with metastasing MTC, showing safety and efficacy of treatment.
116. STIFT A, FRIEDL J, DUBSKY P et al.: Dendritic cell-based vaccination in solid cancer. J. Clin. Oncol. (2003) 21:135-142.
117. STIFT A, SACHET M, YAGUBIAN R et al.: Dendritic cell vaccination in medullary thyroid carcinoma. Clin. Cancer Res. (2004) 10:2944-2953. Clinical trial of DC vaccination therapy in patients with metastasing MTC, showing tumour response in four out of ten treated cases.
118. POWELL DJ JR, EISENLOHR LC, ROTHSTEIN JL: A thyroid tumor-specific antigen formed by the fusion of two self proteins. J. Immunol. (2003) 170:861-869. Investigation of the immunogenicity of RET/PTC3, a thyroid tumour-specific fusion protein expressed in thyroid carcinoma.
119. SHARKEY MS, LIZEE G, GONZALES MI, PATEL S, TOPALIAN SL: CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res. (2004) 64:1595-1599.
120. LAU K, BICKNELL R: Antiangiogenic gene therapy. Gene Ther. (1999) 6:1793-1795.
121. YE C, FENG C, WANG S, LIU X, LIN Y, LI M: Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology (2002) 143:3522-3528.
122. BELLETTI B, FERRARO P, ARRA C et al.: Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogens (1999) 18:4860-4869.
123. KLICHE S, WALTENBERGER J: VEGF receptor signaling and endothelial function. IUBMB Life (2001) 52:61-66.
124. FONG GH, ROSSANT J, GERTSENSTEIN M, BREITMAN ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (1995) 376:66-70.
125. GOLDMAN CK, KENDALL RL, CABRERA G et al.: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA (1998) 95:8795-8800.
126. KENDALL RL, THOMAS KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA (1993) 90:10705-10709.
127. KONG HL, HECHT D, SONG W et al.: Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum. Gene Ther. (1998) 9:823-833.
128. TAKAYAMA K, UENO H, NAKANISHI Y et al.: Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. (2000) 60:2169-2177.
129. YE C, FENG C, WANG S et al.: sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology (2004) 145:817-822. Transfer of sFlt-1 gene effectively inhibits the growth of xenografted human FTC thyroid tumours in immunodeficient mice.
130. O'REILLY MS: Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin. Cancer Res. (2002) 8:3309-3310.
131. MAUCERI HJ, HANNA NN, BECKETT MA et al.: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (1998) 394:287-291.
132. HUANG X, WONG MK, YI H et al.: Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res. (2002) 62:5727-5735.
133. YOKOYAMA Y, DHANABAL M, GRIFFIOEN AW, SUKHATME VP, RAMAKRISHNAN S: Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. (2000) 60:2190-2196.
134. BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274:373-376.
135. PORTELLA G, SCALA S, VITAGLIANO D, VECCHIO G, FUSCO A: ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. (2002) 87:2525-2531. Efficacy of the d/1520 oncotytic adenovirus in an ATC animal model.
136. PORTELLA G, PACELLI R, LIBERTINI S et al.: ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J. Clin. Endocrinol. Metab. (2003) 88:5027-5032.
137. BERLINGIERI MT, SANTORO M, BATTAGLIA C, GRIECO M, FUSCO A: The Adenovirus E1A gene blocks the differentiation of a thyroid epithelial cell line, however the neoplastic phenotype is achieved only after cooperation with other oncogenes. Oncogene (1993) 8:249-255.
138. NEMUNAITIS J, CUNNINGHAM C, BUCHANAN A et al.: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. (2001) 8:746-759.
139. NAGAYAMA Y, NISHIHARA E, NAMBA H et al.: Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system. Cancer Gene Ther. (2001) 8:36-44.
140. SRINIVASAPPA J, GARZELLI C, ONODERA T, RAY U, NOTKINS AL: Virus-induced thyroiditis. Endocrinology (1988) 122:563-566.
141. ATTA MS, IRVING WL, POWELL RJ, TODD I: Enhanced expression of MHC class I molecules on cultured human thyroid follicular cells infected with reovirus through induction of type 1 interferons. Clin. Exp. Immunol. (1995) 101:121-126.
142. NORMAN KL, LEE PW: Reovirus as a novel oncolytic agent. J. Clin. Invest. (2000) 105:1035-1038.
143. STRONG JE, COFFEY MC, TANG D, SABININ P, LEE PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. (1998) 17:3351-3362.
144. ONODERA T, AWAYA A: Anti-thyroglobulin antibodies induced with recombinant reovirus infection in BALB/c mice. Immunology (1990) 71:581-585.
145. GAULTON GN, STEIN ME, SAFKO B, STADECKER MJ: Direct induction of Ia antigen on murine thyroid-derived epithelial cells by reovirus. J. Immunol. (1989) 142:3821-3825.
146. NEUFELD DS, PLATZER M, DAVIES TF: Reovirus induction of MHC class II antigen in rat thyroid cells. (1989) Endocrinology 124:543-545.